Ovoca Bio PLC
LSE:OVB

Watchlist Manager
Ovoca Bio PLC Logo
Ovoca Bio PLC
LSE:OVB
Watchlist
Price: 1.6 GBX Market Closed
Market Cap: 1.3m GBX
Have any thoughts about
Ovoca Bio PLC?
Write Note

Ovoca Bio PLC
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ovoca Bio PLC
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Ovoca Bio PLC
LSE:OVB
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Perrigo Company PLC
NYSE:PRGO
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
Net Issuance of Common Stock
-$390.9m
CAGR 3-Years
N/A
CAGR 5-Years
8%
CAGR 10-Years
-47%
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Net Issuance of Common Stock
$15.1m
CAGR 3-Years
224%
CAGR 5-Years
162%
CAGR 10-Years
-19%
Cosmo Pharmaceuticals NV
SIX:COPN
Net Issuance of Common Stock
-€1.4m
CAGR 3-Years
48%
CAGR 5-Years
46%
CAGR 10-Years
27%
No Stocks Found

Ovoca Bio PLC
Glance View

Market Cap
1.4m GBX
Industry
Pharmaceuticals

Ovoca Bio Plc is a clinical-stage biopharmaceutical company. The company is headquartered in Dublin, Dublin and currently employs 5 full-time employees. The firm is engaged in identifying and developing therapeutics targeting the treatment of female sexual dysfunction. The Company’s product BP101 is a synthetic peptide, administered through a nasal spray that is being developed for the treatment of female sexual dysfunction-hypoactive sexual desire disorder (HSDD). The Company’s subsidiaries include Silver Star Ltd, Bulun LLC, Magsel LLC, IVIX LLC and OVB (Australia) Pty Ltd. The firm operates in Ireland, the United Kingdom (UK) and Russia.

OVB Intrinsic Value
2.98 GBX
Undervaluation 46%
Intrinsic Value
Price

See Also

Back to Top